The tragic thing of course, Darren Stehle , is that HIV is no longer a death sentence.
There’s no need to feel fatalistic.
There’s so much misinformation, even in communities of gay men, about HIV.
As to drug resistance, by the way, the risk is higher with PrEP than with HAART, which almost completely shuts down the possibility of viral replication.
Even with PrEP, though, the risk is low.
Another thing to think about. Truvada is the only commercially available PrEP formulation right now.
That’s not to say that other antiretrovirals would not be useful as PrEP.
Any broad resistance that developed down the road to Truvada could be quickly countered with new PrEP formulations.
PrEP is part of the broader-based TASP strategy.
Treatment as prevention.
The point is to reduce HIV circulation to the point where it’s no longer prevalent.
Given how rates of new HIV infections in North America have plummeted in most at-risk populations, the strategy is working.
Even without treatment to full viral eradication, we’re well on the way to making HIV a rare phenomenon.